CRESCENT BIOPHARMA, INC. Cash and Cash Equivalents, Period Increase (Decrease)
CRESCENT BIOPHARMA, INC. (CBIO) reported Cash and Cash Equivalents, Period Increase (Decrease) of $118.71 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-03
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $118.71M.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $11.05M.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$6.28M.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $84.56M, a 493.17% increase year-over-year.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $83.88M.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$6.76M.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$8.40M, a 115.88% decline from fiscal 2014.
- CRESCENT BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $52.89M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 130 month |
|---|---|---|---|---|---|
| 2018-03-31 | $118.71M 10-Q · filed 2018-05-03 | $129.76M derived: sum of 2 quarters · filed 2018-05-03 | $123.48M derived: sum of 3 quarters · filed 2018-05-03 | $208.04M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-12-31 | $11.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $4.78M derived: sum of 2 quarters · filed 2018-03-06 | $89.33M derived: sum of 3 quarters · filed 2018-03-06 | $83.88M 10-K · filed 2018-03-06 | |
| 2017-09-30 | -$6.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $78.28M derived: sum of 2 quarters · filed 2017-11-08 | $72.83M 10-Q · filed 2017-11-08 | $67.59M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-06-30 | $84.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $79.11M 10-Q · filed 2017-08-03 | $73.87M derived: sum of 3 quarters · filed 2018-05-03 | $66.06M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-03-31 | -$5.45M 10-Q · filed 2018-05-03 | -$10.69M derived: sum of 2 quarters · filed 2018-05-03 | -$18.49M derived: sum of 3 quarters · filed 2018-05-03 | -$4.24M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2016-12-31 | -$5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$13.04M derived: sum of 2 quarters · filed 2018-03-06 | $1.21M derived: sum of 3 quarters · filed 2018-03-06 | -$6.76M 10-K · filed 2018-03-06 | |
| 2016-09-30 | -$7.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $6.45M derived: sum of 2 quarters · filed 2017-11-08 | -$1.52M 10-Q · filed 2017-11-08 | -$8.48M derived: sum of 4 quarters · filed 2018-03-06 | |
| 2016-06-30 | $14.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $6.28M 10-Q · filed 2017-08-03 | -$674.65K derived: sum of 3 quarters · filed 2018-03-06 | $12.85M derived: sum of 4 quarters · filed 2018-03-06 | |
| 2016-03-31 | -$7.97M 10-Q · filed 2017-05-08 | -$14.93M derived: sum of 2 quarters · filed 2018-03-06 | -$1.40M derived: sum of 3 quarters · filed 2018-03-06 | -$7.74M derived: sum of 4 quarters · filed 2018-03-06 | |
| 2015-12-31 | -$6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $6.57M derived: sum of 2 quarters · filed 2018-03-06 | $235.67K derived: sum of 3 quarters · filed 2018-03-06 | -$8.40M 10-K · filed 2018-03-06 | |
| 2015-09-30 | $13.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $7.19M derived: sum of 2 quarters · filed 2016-11-04 | -$1.44M 10-Q · filed 2016-11-04 | -$7.60M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | -$6.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$14.96M 10-Q · filed 2016-08-04 | -$21.13M derived: sum of 3 quarters · filed 2017-03-01 | -$25.98M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | -$8.63M 10-Q · filed 2016-05-04 | -$14.80M derived: sum of 2 quarters · filed 2017-03-01 | -$19.65M derived: sum of 3 quarters · filed 2017-03-01 | -$10.40M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | -$6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$11.02M derived: sum of 2 quarters · filed 2017-03-01 | -$1.77M derived: sum of 3 quarters · filed 2017-03-01 | $52.89M 10-K · filed 2017-03-01 | |
| 2014-09-30 | -$4.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $4.40M derived: sum of 2 quarters · filed 2015-11-12 | $59.05M 10-Q · filed 2015-11-12 | $53.67M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $9.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $63.91M 10-Q · filed 2015-08-06 | $58.53M derived: sum of 3 quarters · filed 2016-02-29 | $55.44M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $54.66M 10-Q · filed 2015-05-05 | $49.28M derived: sum of 2 quarters · filed 2016-02-29 | $46.19M derived: sum of 3 quarters · filed 2016-02-29 | $43.48M derived: sum of 4 quarters · filed 2016-02-29 | $56.97M 10-Q · filed 2014-05-09 |
| 2013-12-31 | -$5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$8.47M derived: sum of 2 quarters · filed 2016-02-29 | -$11.18M derived: sum of 3 quarters · filed 2016-02-29 | -$15.06M 10-K · filed 2016-02-29 | |
| 2013-09-30 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | -$5.80M derived: sum of 2 quarters · filed 2014-10-31 | -$9.68M 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$6.59M 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | -$3.88M 10-Q · filed 2014-05-09 | ||||
| 2012-12-31 | -$10.80M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |